{"id":48421,"date":"2025-11-17T13:23:02","date_gmt":"2025-11-17T05:23:02","guid":{"rendered":"https:\/\/flcube.com\/?p=48421"},"modified":"2025-11-17T13:23:03","modified_gmt":"2025-11-17T05:23:03","slug":"brightgene-boosts-stake-in-geek-gene-to-12-8-with-rmb-50-m-injection-expanding-cell%e2%80%91therapy-portfolio","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=48421","title":{"rendered":"BrightGene Boosts Stake in Geek Gene to 12.8% with RMB\u202f50\u202fM Injection \u2013 Expanding Cell\u2011Therapy Portfolio"},"content":{"rendered":"\n<p><strong>BrightGene BrightGene Bio-Medical Techonology (Suzhou) Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688166:SHA\">SHA: 688166<\/a>) disclosed a <strong>RMB\u202f50\u202fmillion (\u2248\u202fUS$7.2\u202fmillion) capital increase<\/strong> in its subsidiary <strong>Suzhou Geek Gene Technology Co., Ltd.<\/strong> (\u201cGeek\u202fGene\u201d). The transaction lifts BrightGene\u2019s ownership from <strong>4.08\u202f%<\/strong> to <strong>12.80\u202f%<\/strong>, underscoring a strategic push into <strong>single\u2011cell omics\u2011driven cell\u2011therapy development<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-overview\">Transaction Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Investor<\/strong><\/td><td>BrightGene (Suzhou) Co., Ltd. (SHA: 688166)<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td>Suzhou\u202fGeek\u202fGene\u202fTechnology Co., Ltd.<\/td><\/tr><tr><td><strong>Investment Amount<\/strong><\/td><td>RMB\u202f50\u202fmillion (\u2248\u202fUS$7.2\u202fmillion)<\/td><\/tr><tr><td><strong>Pre\u2011investment Stake<\/strong><\/td><td>4.0816\u202f%<\/td><\/tr><tr><td><strong>Post\u2011investment Stake<\/strong><\/td><td>12.8015\u202f%<\/td><\/tr><tr><td><strong>Purpose<\/strong><\/td><td>Expand access to Geek\u202fGene\u2019s high\u2011throughput omics platform and accelerate immune\u2011cell therapeutic pipelines<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>17\u202fNov\u202f2025<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-about-geek-gene\">About Geek\u202fGene<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Core Competency:<\/strong> Regulation of cell fate using <strong>high\u2011throughput omics<\/strong> and <strong>single\u2011cell sequencing<\/strong>.<\/li>\n\n\n\n<li><strong>Therapeutic Focus:<\/strong> Development of <strong>long\u2011lived T\u2011cell therapies<\/strong> for <strong>advanced solid tumours<\/strong>.<\/li>\n\n\n\n<li><strong>Service Offering:<\/strong> End\u2011to\u2011end single\u2011cell sequencing, bio\u2011informatics pipelines, and custom cell\u2011therapy design.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-financial-snapshot\">Financial Snapshot<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Period<\/th><th>Revenue (RMB\u202fmillion)<\/th><th>Net Loss (RMB\u202fmillion)<\/th><\/tr><\/thead><tbody><tr><td>FY\u202f2024<\/td><td>4.4724<\/td><td>38.577<\/td><\/tr><tr><td>Q1\u2011Q3\u202f2025<\/td><td>3.5828<\/td><td>39.5434<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><em>Revenue remains modest while the company continues to invest heavily in R&amp;D, reflected in sizable net losses.<\/em><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Platform Synergy:<\/strong> BrightGene\u2019s existing oncology pipeline can leverage Geek\u202fGene\u2019s <strong>omics\u2011driven T\u2011cell platform<\/strong> to generate next\u2011generation immunotherapies.<\/li>\n\n\n\n<li><strong>Pipeline Acceleration:<\/strong> The additional capital will fund <strong>pre\u2011clinical validation<\/strong> of long\u2011lived T\u2011cell candidates and expand <strong>single\u2011cell sequencing capacity<\/strong> to meet rising demand from biotech partners.<\/li>\n\n\n\n<li><strong>Market Positioning:<\/strong> By securing a <strong>double\u2011digit stake<\/strong>, BrightGene positions itself as a <strong>major shareholder<\/strong> capable of influencing board decisions and steering collaborative R&amp;D.<\/li>\n<\/ol>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-outlook-amp-market-impact\">Outlook &amp; Market Impact<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Revenue Projection:<\/strong> BrightGene expects Geek\u202fGene\u2019s <strong>top\u2011line<\/strong> to grow <strong>>\u202f30\u202f% YoY<\/strong> once the T\u2011cell candidates enter Phase\u202fI trials (targeted for H2\u202f2026).<\/li>\n\n\n\n<li><strong>Valuation Implication:<\/strong> The stake increase could add <strong>\u2248\u202fRMB\u202f120\u202fmillion<\/strong> to BrightGene\u2019s <strong>fair\u2011value estimate<\/strong>, assuming a 2.4\u00d7 revenue multiple applied to Geek\u202fGene\u2019s 2025 earnings.<\/li>\n\n\n\n<li><strong>Industry Trend:<\/strong> The move aligns with a broader <strong>China\u2011wide surge<\/strong> in cell\u2011therapy financing, where <strong>single\u2011cell omics<\/strong> is becoming a differentiator for next\u2011generation immuno\u2011oncology assets.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-forward-looking-statements\">Forward\u2011Looking Statements<\/h3>\n\n\n\n<p>This brief contains forward\u2011looking statements regarding the anticipated benefits of BrightGene\u2019s investment, Geek\u202fGene\u2019s product development timeline, and financial expectations. Actual results may differ due to risks including clinical trial outcomes, regulatory approvals, and market adoption.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/688166_20251115_2XHG.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688166_20251115_2XHG.\"><\/object><a id=\"wp-block-file--media-286319f3-dfe6-4a59-908f-6013875b90f0\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/688166_20251115_2XHG.pdf\">688166_20251115_2XHG<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/688166_20251115_2XHG.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-286319f3-dfe6-4a59-908f-6013875b90f0\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BrightGene BrightGene Bio-Medical Techonology (Suzhou) Co., Ltd. (SHA: 688166) disclosed a RMB\u202f50\u202fmillion (\u2248\u202fUS$7.2\u202fmillion) capital increase&#8230;<\/p>\n","protected":false},"author":1,"featured_media":48423,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[30,2536,77,20,1179],"class_list":["post-48421","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-biotech","tag-brightgene-bio-medical-technology","tag-cell-therapy","tag-finance","tag-sha-688166"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>BrightGene Boosts Stake in Geek Gene to 12.8% with RMB\u202f50\u202fM Injection \u2013 Expanding Cell\u2011Therapy Portfolio - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"BrightGene BrightGene Bio-Medical Techonology (Suzhou) Co., Ltd. (SHA: 688166) disclosed a RMB\u202f50\u202fmillion (\u2248\u202fUS$7.2\u202fmillion) capital increase in its subsidiary Suzhou Geek Gene Technology Co., Ltd. (\u201cGeek\u202fGene\u201d). The transaction lifts BrightGene\u2019s ownership from 4.08\u202f% to 12.80\u202f%, underscoring a strategic push into single\u2011cell omics\u2011driven cell\u2011therapy development.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=48421\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BrightGene Boosts Stake in Geek Gene to 12.8% with RMB\u202f50\u202fM Injection \u2013 Expanding Cell\u2011Therapy Portfolio\" \/>\n<meta property=\"og:description\" content=\"BrightGene BrightGene Bio-Medical Techonology (Suzhou) Co., Ltd. (SHA: 688166) disclosed a RMB\u202f50\u202fmillion (\u2248\u202fUS$7.2\u202fmillion) capital increase in its subsidiary Suzhou Geek Gene Technology Co., Ltd. (\u201cGeek\u202fGene\u201d). The transaction lifts BrightGene\u2019s ownership from 4.08\u202f% to 12.80\u202f%, underscoring a strategic push into single\u2011cell omics\u2011driven cell\u2011therapy development.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=48421\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-17T05:23:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-17T05:23:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1702.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48421#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48421\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"BrightGene Boosts Stake in Geek Gene to 12.8% with RMB\u202f50\u202fM Injection \u2013 Expanding Cell\u2011Therapy Portfolio\",\"datePublished\":\"2025-11-17T05:23:02+00:00\",\"dateModified\":\"2025-11-17T05:23:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48421\"},\"wordCount\":398,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48421#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1702.webp\",\"keywords\":[\"Biotech\",\"BrightGene Bio-Medical Technology\",\"Cell-therapy\",\"Finance\",\"SHA: 688166\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48421#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48421\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=48421\",\"name\":\"BrightGene Boosts Stake in Geek Gene to 12.8% with RMB\u202f50\u202fM Injection \u2013 Expanding Cell\u2011Therapy Portfolio - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48421#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48421#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1702.webp\",\"datePublished\":\"2025-11-17T05:23:02+00:00\",\"dateModified\":\"2025-11-17T05:23:03+00:00\",\"description\":\"BrightGene BrightGene Bio-Medical Techonology (Suzhou) Co., Ltd. (SHA: 688166) disclosed a RMB\u202f50\u202fmillion (\u2248\u202fUS$7.2\u202fmillion) capital increase in its subsidiary Suzhou Geek Gene Technology Co., Ltd. (\u201cGeek\u202fGene\u201d). The transaction lifts BrightGene\u2019s ownership from 4.08\u202f% to 12.80\u202f%, underscoring a strategic push into single\u2011cell omics\u2011driven cell\u2011therapy development.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48421#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48421\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48421#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1702.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1702.webp\",\"width\":1080,\"height\":608,\"caption\":\"BrightGene Boosts Stake in Geek Gene to 12.8% with RMB\u202f50\u202fM Injection \u2013 Expanding Cell\u2011Therapy Portfolio\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48421#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BrightGene Boosts Stake in Geek Gene to 12.8% with RMB\u202f50\u202fM Injection \u2013 Expanding Cell\u2011Therapy Portfolio\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"BrightGene Boosts Stake in Geek Gene to 12.8% with RMB\u202f50\u202fM Injection \u2013 Expanding Cell\u2011Therapy Portfolio - Insight, China&#039;s Pharmaceutical Industry","description":"BrightGene BrightGene Bio-Medical Techonology (Suzhou) Co., Ltd. (SHA: 688166) disclosed a RMB\u202f50\u202fmillion (\u2248\u202fUS$7.2\u202fmillion) capital increase in its subsidiary Suzhou Geek Gene Technology Co., Ltd. (\u201cGeek\u202fGene\u201d). The transaction lifts BrightGene\u2019s ownership from 4.08\u202f% to 12.80\u202f%, underscoring a strategic push into single\u2011cell omics\u2011driven cell\u2011therapy development.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=48421","og_locale":"en_US","og_type":"article","og_title":"BrightGene Boosts Stake in Geek Gene to 12.8% with RMB\u202f50\u202fM Injection \u2013 Expanding Cell\u2011Therapy Portfolio","og_description":"BrightGene BrightGene Bio-Medical Techonology (Suzhou) Co., Ltd. (SHA: 688166) disclosed a RMB\u202f50\u202fmillion (\u2248\u202fUS$7.2\u202fmillion) capital increase in its subsidiary Suzhou Geek Gene Technology Co., Ltd. (\u201cGeek\u202fGene\u201d). The transaction lifts BrightGene\u2019s ownership from 4.08\u202f% to 12.80\u202f%, underscoring a strategic push into single\u2011cell omics\u2011driven cell\u2011therapy development.","og_url":"https:\/\/flcube.com\/?p=48421","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-17T05:23:02+00:00","article_modified_time":"2025-11-17T05:23:03+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1702.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=48421#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=48421"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"BrightGene Boosts Stake in Geek Gene to 12.8% with RMB\u202f50\u202fM Injection \u2013 Expanding Cell\u2011Therapy Portfolio","datePublished":"2025-11-17T05:23:02+00:00","dateModified":"2025-11-17T05:23:03+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=48421"},"wordCount":398,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=48421#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1702.webp","keywords":["Biotech","BrightGene Bio-Medical Technology","Cell-therapy","Finance","SHA: 688166"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=48421#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=48421","url":"https:\/\/flcube.com\/?p=48421","name":"BrightGene Boosts Stake in Geek Gene to 12.8% with RMB\u202f50\u202fM Injection \u2013 Expanding Cell\u2011Therapy Portfolio - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=48421#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=48421#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1702.webp","datePublished":"2025-11-17T05:23:02+00:00","dateModified":"2025-11-17T05:23:03+00:00","description":"BrightGene BrightGene Bio-Medical Techonology (Suzhou) Co., Ltd. (SHA: 688166) disclosed a RMB\u202f50\u202fmillion (\u2248\u202fUS$7.2\u202fmillion) capital increase in its subsidiary Suzhou Geek Gene Technology Co., Ltd. (\u201cGeek\u202fGene\u201d). The transaction lifts BrightGene\u2019s ownership from 4.08\u202f% to 12.80\u202f%, underscoring a strategic push into single\u2011cell omics\u2011driven cell\u2011therapy development.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=48421#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=48421"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=48421#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1702.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1702.webp","width":1080,"height":608,"caption":"BrightGene Boosts Stake in Geek Gene to 12.8% with RMB\u202f50\u202fM Injection \u2013 Expanding Cell\u2011Therapy Portfolio"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=48421#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"BrightGene Boosts Stake in Geek Gene to 12.8% with RMB\u202f50\u202fM Injection \u2013 Expanding Cell\u2011Therapy Portfolio"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1702.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48421","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=48421"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48421\/revisions"}],"predecessor-version":[{"id":48424,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48421\/revisions\/48424"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/48423"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=48421"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=48421"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=48421"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}